Robyn Karnauskas
Stock Analyst at Truist Securities
(2.41)
# 3,020
Out of 5,182 analysts
177
Total ratings
43.42%
Success rate
0.19%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $868.27 | +36.13% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.16 | +140.38% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $340.18 | -12.40% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $57.78 | +12.50% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $110.23 | -0.21% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $127.75 | -35.03% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $197.38 | +6.39% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.73 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $180.67 | +88.19% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $0.58 | +4,370.43% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.84 | +280.43% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $744.44 | +52.46% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.44 | +594.44% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $4.85 | +85.57% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $27.85 | -17.41% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $28.62 | +67.71% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $24.95 | +100.40% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $426.01 | +19.25% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $26.79 | +34.38% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $69.22 | -63.88% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.09 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $53.81 | +160.20% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $2.21 | +1,357,366.06% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.31 | +434.35% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $17.90 | +207.26% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $8.13 | +3,836.04% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $44.11 | -65.99% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $868.27
Upside: +36.13%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.16
Upside: +140.38%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $340.18
Upside: -12.40%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $57.78
Upside: +12.50%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $110.23
Upside: -0.21%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $127.75
Upside: -35.03%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $197.38
Upside: +6.39%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.73
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $180.67
Upside: +88.19%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $0.58
Upside: +4,370.43%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.84
Upside: +280.43%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $744.44
Upside: +52.46%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.44
Upside: +594.44%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $4.85
Upside: +85.57%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $27.85
Upside: -17.41%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $28.62
Upside: +67.71%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $24.95
Upside: +100.40%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $426.01
Upside: +19.25%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $26.79
Upside: +34.38%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $69.22
Upside: -63.88%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.09
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $53.81
Upside: +160.20%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $2.21
Upside: +1,357,366.06%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.31
Upside: +434.35%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $17.90
Upside: +207.26%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $8.13
Upside: +3,836.04%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $44.11
Upside: -65.99%